Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women

Basic Details
Date Posted
Tuesday, December 19, 2017
Status
Complete
Medical Product
adalimumab
certolizumab
etanercept
golimumab
infliximab
tumor necrosis factor (TNF) alpha inhibitor
Description

This report contains estimates of use of five tumor necrosis factor (TNF)-alpha inhibitors, etanercept, adalimumab, infliximab, certolizumab, and golimumab, that occurred during a pregnancy resulting in a liveborn delivery, or within 90 days prior to the estimated start of pregnancy. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2004 to September 30, 2015. This request was distributed to 16 Data Partners on June 27, 2017.

Additional Details
FDA Center
CDER
Time Period
January 1, 2004 - September 30, 2015
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Females 15 to 54 years of age
Data Sources
Sentinel Distributed Database (SDD)